New developments in anticoagulation for atrial fibrillation

Current Treatment Options in Cardiovascular Medicine

Volumn 10, Issue 5, 2008, Pages 388-397

  Usman, M Haris U ^a   Notaro, Lawrence A ^a   Patel, Harsh ^a   Ezekowitz, Michael D ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; APIXABAN; ATI 5923; AVE 3247; BETRIXABAN; BIOTINYLATED IDRAPARINUX; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 9 INHIBITOR; CLOPIDOGREL; DABIGATRAN; DU 176B; EMD 503982; ENOXAPARIN; IDRAPARINUX; IRBESARTAN; KETOCONAZOLE; KFA 1982; MACROLIDE; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; PLACEBO; PRT 054021; RIVAROXABAN; SSR 126517E; THROMBIN INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; TTP 889; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN; YM 150;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LIVER TOXICITY; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; STROKE; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 58649086243     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-008-0030-0     Document Type: Review

References (48)

1. Miyasaka Y, Barnes ME, Gersh BJ, et al.: Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006, 114: 119-125.
2. Kannel WB, Abbott RD, Savage DD, et al.: Epidemiologic features of chronic atrial fibrillation: The Framingham Study. N Engl J Med 1982, 306: 1018-1022.
3. Hart RG, Aearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146: 857-867.
4. Bungard TJ, Ghali WA, Teo KK, et al.: Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000, 160: 41-46.
5. Connolly S, Pogue J, Hart R, et al.; ACTIVE Writing Group of the ACTIVE Investigators: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet 2006, 367: 1903-1912.
6. Albers GW, Diener HC, Frison L, et al.; SPORTIF Executive Steering Committee for the SPORTIF V Investigators: Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial. JAMA 2005, 293: 690-698.
7. Executive Steering Committee of the SPORTIF III Investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet 2003, 362: 1691-1698.
8. Mant J, Hobbs FD, Fletcher K, et al.; BAFTA investigators; Midland Research Practices Network (MidReC): Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007, 370: 493-503.
9. ARYx Therapeutics: Pharmacokinetic profile and study evaluation of ATI-5923. Available at www.aryx.com/wt/page/ati5923. Accessed June 2008. Pharmacologic and developmental data on ATI-5923.
10. Carlquist JF, Horne BD, Muhlestein JB, et al.: Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: A prospective study. J Thromb Thrombolysis 2006, 22: 191-197.
11. Bates SM, Weitz JI: The mechanism of action of thrombin inhibitors. J Invasive Cardiol 2000, 12(Suppl F): 27F-32F.
12. Weitz JI, Leslie B, Hudoba M: Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998, 97: 544-552.
13. Kaul S, Diamond GA, Weintraub WS: Trials and tribulations of non-inferiority: The ximelagatran experience. J Am Coll Cardiol 2005, 46: 1986-1995.
14. Wallentin L, Ezekowitz M, Simmers TA, et al.: PETRO-investigators: Safety and efficacy of a new oral direct thrombin inhibitor dabigatran in atrial fibrillation: A dose finding trial with comparison to warfarin. Eur Heart J 2005, 26(Suppl): 482.
15. Mungall D: BIBR-1048 Boehringer Ingelheim. Curr Opin Investig Drugs 2002, 3: 905-907.
16. Ezekowitz MD, Reilly PA, Nehmiz G, et al.: Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007, 100: 1419-1426.
17. The Petro-ex Investigators: Safety and efficacy of extended exposure to several doses of a new oral direct thrombin inhibitor dabigatran etexilate in atrial fibrillation [abstract 5]. Cerebrovasc Dis 2006, 21(Suppl 4): 2.
18. Bauer KA: New Anticoagulants: anti IIa vs anti Xa'is one better? J Thromb Thrombolysis 2006, 21: 67-72.
19. Perzborn E, Strassburger J, Wilmen A, et al.: In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005, 3: 514-521.
20. Mueck W, Becka M, Kubitza D, et al.: Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor xa inhibitor - in healthy subjects. Int J Clin Pharmacol Ther 2007, 45: 335-344.
21. Kubitza D, Becka M, Wensing G, et al.: Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005, 61: 873-880.
22. Kubitza D, Becka M, Mueck W, Zuehlsdorf M: The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban - an oral, direct Factor Xa inhibitor [abstract]. Blood 2006, 108: 905.
23. Kubitza D, Becka M, Zuehlsdorf M, Mueck W: Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007, 47: 218-226.
24. Kubitza D, Becka M, Zuehlsdorf M, Mueck W: Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct Factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006, 46: 549-558.
25. Pinto DJ, Orwat MJ, Koch S, et al.: Discovery of 1-(4-methoxyphenyl)-7 -oxo-6-(4-(4-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007, 50:5339-5356.
26. He K, He B, Grace JE, et al.: Preclinical pharmacokinetics and metabolism of apixaban, a potent and selective Factor Xa inhibitor. Blood 2006, 108: 910.
27. Lassen MR, Davidson BL, Gallus A, et al.: The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007, 5: 2368-2375.
28. Koopman MM, Büller HR: Short-and long-acting synthetic pentasaccharides. J Intern Med 2003, 254: 335-342.
29. Idraparinux shows encouraging results in the prevention of thromboembolic events in patients with atrial fibrillation [press release]. Paris, France: Sanofi-Aventis; 2007. Available at http://en.sanofi-aventis.com/Images/ 070711_idraparinux_en_tcm24-18621.pdf. Accessed June 2008.
30. Agnelli G, Haas S, Ginsberg JS, et al.: A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 2007, 5: 746-753.
31. Agnelli G, Haas SK, Krueger KA, et al.: A phase II study of the safety and efficacy of a novel oral FXa inhibitor (LY-517717) for the prevention of venous thromboembolism following TKR or THR [abstract]. Blood 2005, 106: 278.
32. Turpie AG, Gent M, Bauer K, et al.: Evaluation of the Factor Xa (FXa) inhibitor, PRT054021 (PRT021), against enoxaparin in a randomized trial for the prevention of venous thromboembolic events after total knee replacement (EXPERT) [abstract]. J Thromb Haemost 2007, 5(Suppl 2): P-T-652.
33. Eriksson BI, Turpie AG, Lassen MR, et al.; ONYX study group: A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007, 5: 1660-1665.
34. Zafar MU, Vorchheimer DA, Gaztanaga J, et al.: Anti-thrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007, 98: 883-888.
35. Neels JG, van Den Berg BM, Mertens K, et al.: Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein. Blood 2000, 96: 3459-3465.
36. Lawson JH, Mann KG: Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem 1991, 266: 11317-11327.
37. Ahmad SS, Rawala-Sheikh R, Walsh PN: Platelet receptor occupancy with factor IXa promotes factor X activation. J Biol Chem 1989, 264: 20012-20016.
38. Chow FS, Benincosa LJ, Sheth SB, et al.: Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. Clin Pharmacol Ther 2002, 71: 235-245.
39. Dyke CK, Steinhubl SR, Kleiman NS, et al.: First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006, 114: 2490-2497.
40. Rothlein R, Shen JM, Naser N, et al.: TTP889, a novel orally active partial inhibitor of FIXa inhibits clotting in two A/V shunt models without prolonging bleeding times [abstract]. Blood 2005, 106: 1886.
41. Eriksson BI, Dahl OE, Lassen MR, et al.; for the Fixit Study Group: Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: An exploratory study. J Thromb Haemost 2008, 6: 457-463.
42. Ragni M, Cirillo P, Pascucci I, et al.: Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Circulation 1996, 93: 1913-1918.
43. Himber J, Kirchhofer D, Riederer M, et al.: Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemost 1997, 78: 1142-1149.
44. Pawashe A, Golino P, Ambrosio G, et al.: A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 1994, 74: 56-63.
45. Szalony JA, Suleymanov OD, Salyers AK, et al.: Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: Effects on thrombus formation and bleeding time. Thromb Res 2003, 112: 167-174.
46. Lee A, Agnelli G, Buller H, et al.: Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001, 104: 74-78.
47. Giugliano RP, Wiviott SD, Stone PH, et al.; for ANTHEM-TIMI-32 Investigators: Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: The ANTHEM-TIMI-32 trial. J Am Coll Cardiol 2007, 49: 2398-2407.
48. Shirk RA, Vlasuk GP: Inhibitors of factor VIIa/tissue factor. Arterioscler Thromb Vasc Biol 2007, 27: 1895-1900.